Clinical Observation of Three Dimensional Conformal Radiotherapy with Tamoxifen in Treatment of Postoperative Malignant Glioma

  • Zhou, Shao-Bing (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Liu, Yang-Chen (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Yin, Xiao-Xiang (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Ding, Wen-Xiu (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Guo, Xin-Wei (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Gu, Liang (Department of Radiation Oncology, Affiliated People's Hospital of Yangzhou University) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2015.03.18


Objective: To evaluate the efficacy and adverse effects of three dimensional conformal radiotherapy (3D-CRT) with tamoxifen in treating patients with postoperative malignant glioma. Patients and Methods: 60 patients of postoperative malignant glioma were randomly assigned into two groups, 30 patients were treated with 3D-CRT plus tamoxifen (treatment group), and the other 30 patients with 3D-CRT plus temozolomide (control group). All patients were radiated by 6MV X-ray, 2.0Gy per fraction, once daily, with a total dose (DT) of 56~60Gy. Tamoxifen was delivered at $60mg/m^2/d$, temozolomide was given at $75mg/m^2/d$. All patients were treated with concurrent radiotherapy. Results: One, 2, 3 year survival rates of treatment and control group were 63.3%, 30.0%, 23.0% and 70.0%, 33.3%, 26.7%, respectively (${\chi}^2=0.01$, 0.23, 0.09, P>0.05). The rate of thromboembolism in treatment group was 6.7%. Conclusion: Therapeutic efficacy of two groups was similar, but it was more cost-effective in treatment group, and toxicity did not increase.


Malignant glioma;three dimensional conformal radiotherapy;tamoxifen


  1. Broniscer A, Leite CC, Lanchote, et al (2000). Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. J Clin Oncol, 18, 1246-53.
  2. Flannery TW, Dibiase S, Patel S, et al (2005). A Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for the treatment high-grade gliomas. Int J Radiat Oncol Biol Phys, 82, 739-42.
  3. Liu XX, Cui L, Dong HM (2009). Clinical observation in 3 dimensional conformal radiotherapy (3D-CRT) concurrent chemotherapy in treatment of postoperative cerebral gliomas. China Oncology, 12, 938-42.
  4. Partap S, Fisher PC (2007). Update on new treatments and developments in childhood brain tumors. Curt Opin Pediart, 19, 670-4.
  5. Pashaki AS, Hamed EA, Mohamadian K, et al (2014). Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiform--a single institution report. Asian Pac J Cancer Prev, 15, 2793-6.
  6. Pollack IF, DaRosso RC, Robertson PL, et al (1997). A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res, 3, 1109-15.
  7. Robins H, Won M, Seiferheld WF, et al (2006 ). Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme. Neuro oncolo, 8, 47-52.
  8. Tang Xi, Hu Ya, Xu Yanhua (2009). Clinical research in three-dimensional conformal radiotherapy combined with Temozolomide in the treatment of malignant glioma. Prog Modern Biomedicine, 12, 2885-6.
  9. Tian DS, Liu JL, Xie MJ, et al (2009). Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. J Neurochem, 109, 1658-67.
  10. Wang JJ, Wang G, Du SM, et al (2013). Relations between multidrug resistance and P13K/Akt signaling pathway and treatment progression of glioma. Oncology Progress, 11, 287-91.
  11. Wang LY, Tu QS, Zhou WB, et al (2011). Efficacy and safety of 3-dimensional conformal radiotherapy combined with Temozolomide for glioma. J Central South University, 4, 1106-10.
  12. Yin WB, Yu ZH, Xu GZ, et al (2008). Beijing: Beijing union medical university press, Radiation Oncology, 1122-9.
  13. Zhang W, Couldwell WT, Song H, et al (2000). Tamoxifeninduced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res, 60, 395-400.
  14. Zheng W, Nie Q, Kang JB, et al (2011). Clinical efficacy study of concurrent chemoradiotherapy for patients with postoperative high grade glioma. Chinese J Neuromedicine, 10, 900-4.

Cited by

  1. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016,
  2. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016,